MAMTA PARIKH

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Phase 2

Recruiting

Conditions: Advanced Prostate Adenocarcinoma
Stage III Prostate Cancer AJCC v8
Stage IV Prostate Cancer AJCC v8

Interventions: Drug: Abiraterone
Procedure: Biospecimen Collection
Drug: Darolutamide
Drug: Prednisone

First Posted Date: 2023-12-15

Last Posted Date: 2024-12-18

Lead Sponsor: Mamta Parikh

Target Recruit Count: 75

Registration Number: NCT06173362

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Phase 1

Recruiting

Conditions: Recurrent Non-Muscle Invasive Bladder Carcinoma
Stage 0is Bladder Cancer AJCC v8
Stage 0a Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8

Interventions: Drug: PLZ4-coated paclitaxel loaded micelles (PPM)

First Posted Date: 2023-12-15

Last Posted Date: 2024-12-18

Lead Sponsor: Mamta Parikh

Target Recruit Count: 12

Registration Number: NCT06173349

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1

Recruiting

Conditions: Refractory Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Selinexor

First Posted Date: 2021-04-23

Last Posted Date: 2023-07-03

Lead Sponsor: Mamta Parikh

Target Recruit Count: 12

Registration Number: NCT04856189

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Stage IV Prostate Cancer
Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma

Interventions: Drug: Enzalutamide
Drug: Niclosamide

First Posted Date: 2017-04-21

Last Posted Date: 2023-04-26

Lead Sponsor: Mamta Parikh

Target Recruit Count: 6

Registration Number: NCT03123978

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Metastatic Prostate Carcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Indomethacin

First Posted Date: 2016-10-17

Last Posted Date: 2023-11-29

Lead Sponsor: Mamta Parikh

Target Recruit Count: 38

Registration Number: NCT02935205

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Stage IV Prostate Cancer
Metastatic Prostate Carcinoma

Interventions: Drug: Abiraterone Acetate
Drug: Niclosamide
Drug: Prednisone

First Posted Date: 2016-06-21

Last Posted Date: 2024-12-18

Lead Sponsor: Mamta Parikh

Target Recruit Count: 37

Registration Number: NCT02807805

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy